Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 892 posts  |  Last Activity: 45 minutes ago Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    MIT Technology Review

    by groverneuse 10 hours ago
    kadaicher1 kadaicher1 45 minutes ago Flag

    Yes it is. This is similar to what Tanzi has been saying for some time and has even called PBT2 a possible AD statin. (using statin to describe the process of prevention of aggregation)
    From the article.
    "The hope is that eventually Alzheimer’s could be prevented by regularly checking and treating amyloid levels, much the way heart attacks are averted by monitoring cholesterol."
    I think statements like this have more relevance now with PBT2 now we know the plaque reduction continued out to two years. That little article also contained a very good illustration of the difference between two different people. One can tolerate seriously high levels of plaque. We have seen it in cancer where the same cancer responds differently in different people simply because the cancer is the patients own cells gone imortal, and there will always be differences in how the cell learns to fight off a chemo.
    This is clearly demonstrated in AD with PSEN1, PSEN2 ,APOE4 and other risk genes discovered. It is doubtful a one drug solution will be found.
    Preventing the buildup has to be a good way to fight AD.

    Sentiment: Strong Buy

  • Reply to

    PBT2 inhibits excitotoxity

    by pivalde 13 hours ago
    kadaicher1 kadaicher1 1 hour 11 minutes ago Flag

    Thanks pivalde. It is important to bring these facts to the attention of readers from time to time. Anyone who appreciates how neurons die in neurodegeneration, traumatic brain injury and even stroke will understand the importance of this capability.
    Could you call excitotoxicity a deadly form of brain inflamation.
    In the case of traumatic brain injury this excitotoxicity continues to kill brain cells long after the original injury and anything which could arrest that process would be of value.

    Sentiment: Strong Buy

  • Reply to

    Short Version: PBT2 works in AD.

    by kadaicher1 Aug 26, 2015 9:32 AM
    kadaicher1 kadaicher1 1 hour 27 minutes ago Flag

    I would say amyloid plaque decreasing steadily for 2 years is pretty big news. Just to refresh your memory, this was a biomarker trial with plaque removal as a primary end point.

    Sentiment: Strong Buy

  • There turkeys have no answers, just past posters and prices. They don't seem to understand that buying a stock low is where you make profits. Very soon it will be time to demonstrate that principle again.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 1 hour 51 minutes ago Flag

    That is day and margin traders. Like you. People who identify and hold investments, like Buffet, rarely go under.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 10 hours ago Flag

    I believe you are correct, if this was big pharma this may not have been a problem. As chance would have it this delay helps the biggest pharma catch up. Imagine that.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 10 hours ago Flag

    Also it is not PBT2 which has safely been used in 8 human trials.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 10 hours ago Flag

    Going by his posts in the past as it was happening he has probably taken a 7 figure profit here and is now playing with house money and by definition cannot possibly make a loss. Keep scooping those pennies.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 12 hours ago Flag

    It has been understood for many years the original MPAC CQ is more toxic in dogs than humans. Remember CQ is still freely available in many countries over the counter. The more I learn about it the less I am concerned:-)

    Sentiment: Strong Buy

  • Reply to

    Now 2000 compounds!

    by interesting2me Aug 26, 2015 5:21 AM
    kadaicher1 kadaicher1 12 hours ago Flag

    mkrg, with basher trolls all over the board I think ITM has done a sterling job presenting the positive case. He has just stated a fact above, verifiable in the new annual report.
    434 is advancing to the clinic and that is second iron in the fire capable of going after several diseases.
    AMEN on the low clouds:-)

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 12 hours ago Flag

    CQ was prescribed in the US for 40 years at 600mg.

    I like beagles like everybody. I was involved in one biotech who's data package was knocked back because they didn't overdose the dogs till death so the organs could then be examined. It is very sad and what is required by regulators. Beagles are used because they are placid and easy to control. Many places use them as sniffer dogs because they are inoffensive.
    CQ was used worldwide by millions over 40 years it was on the market. Typical dose in the US was 600mg. In Japan they were using 1200mg. (Degos & Thomas-Lamotte 1977)The problem was the did not think CQ left the gut. Stomach pains were an early sign of overdose and that was often treated in Japan with more CQ. Severe overdose of many medicines can be very dangerous.
    There was never scientific proof that oversosing CQ caused nerve damege, but there was a casual association established. First symptoms to appear were reversable when the dose was discontinued.
    This is all very old info.
    CQ was never banned from many third world countries, is freely available and has been for 70 years or so. Can even be bought from street vendors in some countries with no warnings. Other countries have it on prescription only such as India Taiwan and Malaysia.
    SMON was receding before the drug was banned in some countries.

    Sentiment: Strong Buy

  • Reply to

    Now 2000 compounds!

    by interesting2me Aug 26, 2015 5:21 AM
    kadaicher1 kadaicher1 13 hours ago Flag

    Now that Tanzi has the ability to test drugs AND COMBINATIONS ex vivo, I think a big library like that will become very valuable. Tanzi's "AD in a dish" is being used for fast identification of ideal drug candidates. If it is a game changer, so it that big library of compounds to work with.

    Sentiment: Strong Buy

  • Reply to

    PBT2 inhibits excitotoxity

    by pivalde 13 hours ago
    kadaicher1 kadaicher1 13 hours ago Flag

    I agree. A drug which it now looks like can gently reduce plaque, re establish transition metal homeostasis(balance) and work against excitotoxicity, would be a valuable tool for docs.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 13 hours ago Flag

    Total BS as usual. If you take the trouble to research it, after the Japan problems with SMON they tried to overdose different animals with clioquinol to reproduce the nerve damage and were only able to do it very well in dogs and cats. This has been well known for 4 decades.
    So to be very clear, CQ was dangerous for dogs, but not in humans in the absence of massive overdose. It is quite the opposite to what you said.
    More recently in a human MMyeloma trial humans were dosed up to 3200mg a day before limiting toxicities were encountered. That is almost 7 times Prana's top dose.
    Their phase 1 dose ranging trial in humans went up to 800mg with no problems.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 23 hours ago Flag

    Ditto on the PBT434. Toxicology was completed at the end of last year and now I believe they are identifying the ideal Parkinsonian orphan to go against. One of those unserved orphans, PSP, sent Allon to the wall when they rolled the dice with everything they had and lost, so Prana can take all the time they need to get it right IMO. It is still a year late:-(

    Sentiment: Strong Buy

  • kadaicher1 by kadaicher1 Aug 26, 2015 4:05 PM Flag

    Prana have great scientists, but I will agree they are let down a little by whoever is responsible for getting the Annual report onto the website. How are prospective new investors able to access it at this important point if they don't use HC? That is a trading day gone and it is still not posted in the Prana site news. It is all very well for us to throw opinions around here, but a real investor will want to read it for himself and it is not there.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Aug 26, 2015 3:49 PM Flag

    No, read the report, PBT434 trials next year. It is not a dream but clearly stated in the report. Stop trying to mislead investors bio just to get a cheaper buy in. I guess you didn't miss that 434 point but chose to ignore it in your post, giving a distorted negative outlook. You are pretty transparent. Yes in my opinion anything under a few bucks is a strong buy. I am not a day trader.
    Even though you don't understand the MOA, you don't believe it will reach the point of completing a phase3. If you accept it will reach that point then you should know it will probably be a 10 bagger before then.
    You and I know most institutions don't trade in this price range. I didn't say institutions were stupid for not buying Prana, but pointed out they have backed all the high profile losers over the last decade. I just pointed out they haven't backed a winner and didn't call them stupid.
    I am just an long investor and my opinion of Prana has not changed. In my opinion your opinion changes to suit whichever position you have.
    How can you have a portfolio for unmet drugs:-) If it is unmet needs just ask and I will post them.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Aug 26, 2015 3:21 PM Flag

    What that report failed to state Pivalde is that they tried to see if results were reported elsewhere over the 40 years it was in heavy use worldwide and managed to identify perhaps 100 total cases which MAY have been down to CQ.
    The SMON epidemic was receding before CQ was banned.
    They tried to reproduce the effect in many models and cats and dogs were where they could do it. This effect in dogs has been known to the FDA and everybody else for decades.
    Recently to identify CQ toxic levels in humans a cancer trial in Canada docs had to go to 3200mg per day to get there. Top dose in Prana's trial was 250mg.

    Now the SMON is caused by something stripping the myelin sheath from nerves, which is also what happens to a degree in MS. Here CQ is shown in a MS model to have the opposite effect.
    "Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. "
    [Furthermore, the present study found that post-treatment with CQ also reduced the clinical score of EAE and spinal cord demyelination. ]

    There is little doubt the CQ problem in Japan was caused by overdosing. Stomach cramps caused by CQ overdosing were treated with more CQ while they were looking for a virus.

    To put a damaging hold on Prana at this point is a little suspect.
    [PBT2 has now completed four Phase 1 trials and four Phase 2 trials. Each of the Phase 2 trials had good recruitment rates, high retention and completion rates. Each was reviewed by an independent Data Safety Monitoring Board that did not identify any safety concerns or require alterations to the protocols. Our IMAGINE extension trial invited patients to continue onto a twelve month open label extension study with 82% of the extension trial participants completing the study. All these studies have provided evidence of good safety and tolerability in trial participants for up to two years.]

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Aug 26, 2015 2:47 PM Flag

    Horse sht. Another expert who obviously knows nothing of Prana's history. Long before the the HD trial is over the price will pass 10 bagger. Long before the HD trial is over, phase1s for Parkinsonian orphans will be over and phase 2s will be underway. The Parkinsonian orphan trials are unserved needs and the trials could be quick. With a higher price money will be easier and maybe even a cancer MPAC into the clinic before the HD trials are over.

    Sentiment: Strong Buy

  • Reply to

    Short Version: PBT2 works in AD.

    by kadaicher1 Aug 26, 2015 9:32 AM
    kadaicher1 kadaicher1 Aug 26, 2015 2:40 PM Flag

    Some cherry picking of the AD info. But:
    [However, exploratory information from the Open Label extension phase suggests that for the cohort of 27 trial participants that completed all 24 months (11 from 15 that started IMAGINE on placebo together with 16 of 25 that remained on PBT2 for the 24 months), the amyloid levels decreased in this cohort compared to an historical control group from the Australian Imaging Biomarker and Lifestyle (AIBL) study. Although exploratory, the cohort data encourages exploration of changing brain amyloid in larger well powered trials. ]

    My biggest worry was that the effect would taper off. It didn't. The 15 patient placebo has already been well discredited as for being of any value at all. 11 patients less value, but the overall plaque reduction continued and that is pretty good news. We have target engagement.
    For the record, I agree with Canadian on future trial design. Go all out for cognition with a bigger dose and bigger trial. This biomarker trial was only barely powered to see biomarker shifts and with no chance to see a decent cognition result. Maybe the only biomarker they need is atrophy and CSF in future.

    Sentiment: Strong Buy

PRAN
0.8901-0.0399(-4.29%)Aug 27 3:39 PMEDT